Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors.
about
Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds EnSoluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: effects of adalimumab versus placeboSwitching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study.Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab.Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy--a single centre, open-label study.Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions.Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics RegisterImprovements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies.The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritisRandomized controlled trial of a nurse-led rheumatology clinic for monitoring biological therapy.The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: an Italian multicentre longitudinal observational pilot study.A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritisThe comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study.Is remission a more realistic goal in psoriatic arthritis?Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis.Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: protocol for a prospective, exploratory cohort study.Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissueTreatment recommendations for psoriatic arthritis.Drug persistence, effectiveness and safety assessment of anti-TNF therapies in psoriatic arthritis.Management of psoriatic arthritis from the view of the dermatologist.A review of disease activity measures for psoriatic arthritis: what is the best approach?Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis.Assessing disease activity in psoriasis and psoriatic arthritis: impact on management and therapy.Patient-Reported Outcomes in Psoriatic Arthritis.Fatigue, pain and patient global assessment responses to biological treatment are unpredictable, and poorly inter-connected in individual rheumatoid arthritis patients followed in the daily clinic.Synovial tissue response to treatment in psoriatic arthritis.Axial Disease in Psoriatic Arthritis study: defining the clinical and radiographic phenotype of psoriatic spondyloarthritis.Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA.Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO.Singapore Chapter of Rheumatologists consensus statement on the eligibility for government subsidy of biologic disease modifying anti-rheumatic agents for the treatment of psoriatic arthritis.Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score.Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register.Efficacy and safety of faecal microbiota transplantation in patients with psoriatic arthritis: protocol for a 6-month, double-blind, randomised, placebo-controlled trial.Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy
P2860
Q26862017-6AB6653A-70A2-434F-B041-F3B990EBE7F1Q28475485-526D65B3-FF17-4B1A-A42E-250FD553BE7BQ30612910-C958B992-D42A-4C59-9C02-FD1DECB0141BQ30677867-603CB05D-B5A0-4AA9-B894-01463602990AQ33390403-90E6204B-F737-4E36-9F7F-000CDBE935B4Q33566374-058C54B1-B456-4372-A6C1-AFA408A5798BQ33726924-E83D75B7-C77A-4332-8039-FFC342D14C42Q34017619-CA503A39-B943-425C-BC48-1CACCA4F1C08Q34630959-E38E2154-5441-4DCD-AFD9-F36D0600F239Q34850808-DAB6982F-3664-4799-84D7-F494F167F640Q35132212-C92B80F0-D690-4A62-AF31-FCBECFFEBB88Q35326449-BB6ECBCC-73FC-449C-97A2-2EE73D709BA5Q35953468-EE9E9F31-2935-455D-9FB8-FB37320885C0Q36059579-932E6697-77EC-458F-BE69-1B26E67848A1Q36479450-924A0A25-AB07-43E3-8B2E-638334CE6AE4Q36819032-F4F4BB04-4DB7-45F2-9E1A-0D810BDFD7B3Q37080199-0E22D281-C818-48C5-8F18-45D5EDFB0647Q37245184-FD8BD3A4-42D7-40AE-BE52-DB28AF371E06Q37284516-7E315EF7-24C4-4AE5-A78C-0BBA1722104AQ37826195-EE4C0A08-8EE0-478E-AFCC-97B76F8DD01DQ37930978-53806E8E-B854-4E47-8D23-CEB714317B15Q38236514-B822B801-9042-47E9-AC30-C49EFE3FED56Q38630548-C26A30AF-0CEA-4BA5-9A14-337A5B0C091BQ38710469-DF58C703-43F2-4451-A9F9-4B5DCEF9A9FFQ38822369-CCA706F0-75C6-4F2C-9272-0FD4851DE6BDQ39568753-DB9F9622-EA30-457F-8A25-776FE3EE0DAAQ40576433-EDBD9C11-770A-48AF-96B7-40A866A2F9D5Q41146029-B249D7CB-F77D-4554-BC0D-260015A6C1A6Q41615511-771A5D62-8E0E-470F-A42D-5CA348050762Q42210089-CFF9DE51-D0EF-4B24-9650-DD15F7F04FF2Q46129663-85632E86-20BD-4A80-98C3-2166C7A38895Q46893265-13CE6915-01D5-4BF4-B93F-CDC3EBC9C57DQ48960736-905D08C9-59A0-476E-ABD0-675DE702C77DQ50220930-4758F1A8-0D56-4BDD-82B0-52AB5FE31738Q53828369-294880BD-0FEA-4138-ABEC-05C3810068E9Q56974580-03DD8957-CEDF-467F-9C37-EB59509BFAB4
P2860
Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors.
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Performance of response criter ...... ur necrosis factor inhibitors.
@ast
Performance of response criter ...... ur necrosis factor inhibitors.
@en
type
label
Performance of response criter ...... ur necrosis factor inhibitors.
@ast
Performance of response criter ...... ur necrosis factor inhibitors.
@en
prefLabel
Performance of response criter ...... ur necrosis factor inhibitors.
@ast
Performance of response criter ...... ur necrosis factor inhibitors.
@en
P2093
P2860
P356
P1476
Performance of response criter ...... ur necrosis factor inhibitors.
@en
P2093
A Kavanaugh
J R Kalden
P L C M Van Riel
P2860
P304
P356
10.1136/ARD.2006.051706
P407
P577
2006-04-27T00:00:00Z